---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277523"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:16:45.490134+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data

## Summary
- Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.
- Phase 3 NEAT enrollment completed (105 participants); topline results expected first quarter 2026.
- iDSMB recommended study continue without modifications; 100% of patients chose open-label extension.
- Net loss $13.3M ($0.25/sh); R&D expenses $8.1M, G&A expenses $3.3M for Q3 2025.
- FDA Fast Track designation; NDA submission planned H2 2026 assuming positive study results.

## SEC filing metadata
- accession: 0001193125-25-277523
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/0001193125-25-277523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/qncx-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277523
- JSON: https://secwatch.observer/filing/0001193125-25-277523.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277523.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.